Caspofungin: new indication. Same indications in children as in adults.
Caspofungin is no more effective than amphotericin B in children but its adverse effect profile is somewhat different. Caspofungin has not been compared with azole antifungals.
D000935:Antifungal Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D001228:Aspergillosis / Q000188:drug therapy; D002177:Candidiasis / Q000188:drug therapy; D000077336:Caspofungin; D002648:Child; D002675:Child, Preschool; D004311:Double-Blind Method; D017277:Drug Approval; D054714:Echinocandins / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D005060:Europe; D006801:Humans; D055666:Lipopeptides; D009181:Mycoses / Q000188:drug therapy; D016032:Randomized Controlled Trials as Topic
D000935:Antifungal Agents; D054714:Echinocandins; D055666:Lipopeptides; D000077336:Caspofungin